Katherine Cunha, NP
Articles
Clinical Experience of Lorlatinib ALK+ NSCLC Patients
Dr. Kim discusses her experience with lorlatinib in real-world settings for ALK+ NSCLC, highlighting both the benefits and challenges of incorporating it into clinical practice.
Overview of Current Treatment Landscape of ALK Inhibitors
Dr. Garon describes the current treatment landscape for metastatic ALK+ NSCLC and explores alternative treatment options that could have been considered for these patients.
Overview of Efficacy of Lorlatinib in the Treatment of ALK+ NSCLC
Dr. Kim provides an overview of the clinical evidence supporting lorlatinib as a first-line therapy for ALK+ metastatic NSCLC, focusing on the key efficacy outcomes from the phase 3 CROWN trial.
Barriers and Challenges in Biomarker Testing for ALK+ NSCLC
Dr. Garon discusses the factors that make a patient a strong candidate for ALK inhibitor therapy in ALK+ NSCLC, the importance of biomarker testing in guiding treatment selection, and his approach to testing along with challenges encountered, especially in community settings.
Evaluating Treatment Options of EGFR Inhibitors
Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.
Clinical Experience of Amivantamab in EGFR+ NSCLC Patients
Dr. Kim shares his clinical experience with amivantamab in real-world practice for EGFR+ NSCLC, discussing both the benefits and challenges of incorporating it into treatment protocols.
Overview of FLAURA and MARIPOSA-2 Clinical Trials
Dr. Kim reviews key clinical evidence from the FLAURA trial for osimertinib as a first-line therapy in EGFR+ metastatic NSCLC and discusses the MARIPOSA 2 trial supporting amivantamab with chemotherapy as the preferred second-line option.
The Impact of Molecular Testing on Treatment Choices for NSCLC
A discussion with Dr. Garon highlights patient selection for EGFR inhibitor therapy in EGFR+ NSCLC, emphasizing the critical role of biomarker testing, testing approaches, and overcoming barriers in community settings.
Robert’s Journey With EGFR+ Metastatic NSCLC
The video segment profiles a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.
